Fig. 1: Mechanism of action of CD3+ bispecific T-cell redirection in cancer.
From: Overcoming the challenges associated with CD3+ T-cell redirection in cancer
The schematic depicts an IgG-like bispecific antibody simultaneously binding a tumour-associated antigen (TAA) on a cancer cell and CD3 epsilon on a T cell to redirect the cytotoxic activity of T cells to these tumour cells.
